Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)-Reference-Cited by-同舟云学术

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Published:2022-08 Issue:4 Volume:7 Page:100552
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Hartlapp I.,Valta-Seufzer D.,Siveke J.T.,Algül H.,Goekkurt E.,Siegler G.,Martens U.M.,Waldschmidt D.,Pelzer U.,Fuchs M.,Kullmann F.,Boeck S.,Ettrich T.J.,Held S.,Keller R.,Anger F.,Germer C.T.,Stang A.,Kimmel B.,Heinemann V.,Kunzmann V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial;Kunzmann;Lancet Gastroenterol Hepatol,2021

2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial;Mukherjee;Lancet Oncol,2013

3. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer;Hurt;Br J Cancer,2017

4. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial;Hammel;JAMA,2016

5. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial;Sohal;JAMA Oncol,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm;Cancer Treatment Reviews;2024-06

2. Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma;HPB;2024-06

3. Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”;ESMO Open;2024-05

4. The value of CA19-9 dynamics in decision making for treatment of locally advanced pancreatic cancer;Gland Surgery;2024-03

5. Stereotactic body radiotherapy for pancreatic cancer – A systematic review of prospective data;Clinical and Translational Radiation Oncology;2024-03